Avalo Therapeutics
AVTX
AVTX
22 hedge funds and large institutions have $863K invested in Avalo Therapeutics in 2023 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
95% less capital invested
Capital invested by funds: $16M → $863K (-$15.1M)
Holders
22
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$701K | |
| 2 | +$91.6K | |
| 3 | +$82.8K | |
| 4 |
BlackRock
New York
|
+$59.9K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$57.9K |
Top Sellers
| 1 | -$7.73M | |
| 2 | -$1.93M | |
| 3 | -$831K | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$708K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$700K |